# Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia

> **NCT03957915** · EARLY_PHASE1 · COMPLETED · sponsor: **Institut Paoli-Calmettes** · enrollment: 33 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia Recurrent
- Acute Lymphoblastic Leukemia, in Relapse
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukaemia Recurrent
- Mixed Phenotype Acute Leukemia

## Interventions

- **DRUG:** INA03 administration

## Key facts

- **NCT ID:** NCT03957915
- **Lead sponsor:** Institut Paoli-Calmettes
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-29
- **Primary completion:** 2024-07-15
- **Final completion:** 2025-02-24
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2025-08-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03957915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03957915, "Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03957915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*